Analysis of Wilms Tumor Gene (WT1) Expression in Acute Leukemia Patients with Special Reference to the Differential Diagnosis between Eosinophilic Leukemia and Idiopathic Hypereosinophilic Syndromes

References

• Gessler M., Poustka A., Cavenee W., Neve R. L., Orkin S. H., Bruns G. A. P. Homozygous deletions in Wilms'tumours of a zinc- finger gene identified by chromosome jumping. Nature (Lond) 1990; 343: 774–778
   PubMed Web of Science ®Google Scholar
• Call K. M., Glaser T., Ito C. Y., Buckler A. J., PeUetier J., Haber D. A., Rose E. A., Krai A., Yeger H., Lewis W. H., Jones C., Housmann D. E. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509–520
   PubMed Web of Science ®Google Scholar
• Rose E. A., Glaser T., Jones C., Smith C. L., Lewis W. H., Call K. M., Minden M., Champagne E. L.B., Yeger H., Housemann D. E. Complete physical map of the WAGR region of 11p13 localizes a candidate Wilms' tumor gene. Cell 1990; 60: 495–510
   PubMed Web of Science ®Google Scholar
• Pritchard-Jones K., Fleming S., Davidson D., Bickmore W., Porteous D., Gosden C., Bard J., Buckler A., Pelletier J., Housman D., et al. The candidate Wilms' tumour gene is involved in genitourinary development. Nature 1990; 346: 194–197
   PubMed Web of Science ®Google Scholar
• Armstrong J. F., Pritchard-Jones K., Bickmore W. A., Hastie N. D., Bard J. B. The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. Mech Dev 1993; 40: 85–97
   PubMed Web of Science ®Google Scholar
• Kudoh T., Ishidate T., Moriyama M., Toyoshima K., Akiyama T. G1 phase arrest induced by Wilms tumor protein WT1 is abrogated by cyclin/CDK complexes. Proc Natl Acad Sci USA 1995; 92: 4517–4521
   PubMed Web of Science ®Google Scholar
• Bruening W., Gros P., Sato T., Stanimir J., Nakamura Y., Housman D., Pelletier J. Analysis of the 11p13 Wilms' tumor suppressor gene (WT1) in ovarian tumors. Cancer Invest 1993; 11: 393–399
   PubMed Web of Science ®Google Scholar
• Viel A., Giannini F., Capozzi E., Canzonieri V., Scarabelli C., Gloghini A., Boiocchi M. Molecular mechanisms possibly affecting WT1 function in human ovarian tumors. Int J Cancer 1994; 57: 515–521
   PubMed Web of Science ®Google Scholar
• Silberstein G. B., Van Horn K., Strickland P., Roberts C. T., Jr., Daniel C. W. Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci USA 1997; 94: 8132–8137
   PubMed Web of Science ®Google Scholar
• Rodeck U., Bossier A., Kari C., Humphreys C. W., Gyorfi T., Maurer J., Thiel E., Menssen H. D. Expression of the WT1 Wilms' tumor gene by normal and malignant human melanocytes. Int J Cancer 1994; 59: 78–82
   PubMed Web of Science ®Google Scholar
• Park S., Schalling M., Bernard A., Maheswaran S., Shipley G. C., Roberts D., Fletcher J., Shipman R., Rheinwald J., Demetri G., et al. The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 1993; 4: 415–420
   PubMed Web of Science ®Google Scholar
• Walker C., Rutten R., Yuan X., Pass H., Mew D. M., Everitt J. Wilms' tumor suppressor gene expression in rat and human mesothelioma. Cancer Research 1994; 54: 3101–3106
   PubMed Web of Science ®Google Scholar
• Langerak A. W., Williamson K. A., Miyagawa K., Hagemeijer A., Versnel M. A., Hastie N. D. Expression of the Wilms' tumor gene WT1 in human malignant mesothelioma cell lines and relationship to platelet-derived growth factor A and insulin-like growth factor 2 expression. Genes Chromosomes Cancer 1995; 12: 87–96
   PubMed Web of Science ®Google Scholar
• Amin K. M., Litzky L. A., Smythe W. R., Mooney A. M., Morris J. M., Mews D. J., Pass H. I., Kari C., Rodeck U., Rauscher F. J., 3rd, et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995; 146: 344–356
   PubMed Web of Science ®Google Scholar
• Ladanyi M., Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res 1994; 54: 2837–2840
   PubMed Web of Science ®Google Scholar
• Campbell C. E., Kuriyan N. P., Rackley R. R., Cauffield M. J., Tubbs R., Finke J., Williams B. R. Constitutive expression of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma. Int J Cancer 1998; 78: 182–188
   PubMed Web of Science ®Google Scholar
• Oji Y., Ogawa H., Tamaki H., Oka Y., Tsuboi A., Kim E. H., Soma T., Tatekawa T., Kawakami M., Asada M., Kish-Imoto T., Sugiyama H. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999; 90: 194–204
   PubMedGoogle Scholar
• Menssen H. D., Bertelmann E., Bartelt S., Schmidt R. A., Pecher G., Schramm K., Thiel E. Wilms' tumor gene (WT1) expression in Lung cancer, colon cancer and glioblastomaa cell lines, compared to freshly isolated tumor specimen. 1999, submitted
   Google Scholar
• Drummond I. A., Madden S. L., Rohwer-Nutter P., Bell G. I., Sukhatme V. P., Rauscher F. J.D. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 1992; 257: 674–678
   PubMed Web of Science ®Google Scholar
• Werner H., Re G. G., Drummond I. A., Sukhatme V. P., Rauscher F. J.D., Sens D. A., Garvin A. J., LeRoith D., Roberts C. T., Jr. Increased expression of the insulin-like growth factor I receptor gene, IGFIR, in Wilms tumor is correlated with modulation of IGFIR promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci USA 1993; 90: 5828–5832
   PubMed Web of Science ®Google Scholar
• Gashler A. L., Bonthron D. T., Madden S. L., Rauscher F. J.D., Collins T., Sukhatme V. P. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. Proc Natl Acad Sci USA 1992; 89: 10984–10988
   PubMed Web of Science ®Google Scholar
• Wang Z. Y., Madden S. L., Deuel T. F., Rauscher F. J.D. The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene. J Biol Chem 1992; 267: 21999–22002
   PubMed Web of Science ®Google Scholar
• Englert C., Hou X., Maheswaran S., Bennett P., Ngwu C., Re G. G., Garvin A. J., Rosner M. R., Haber D. A. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. Embo J 1995; 14: 4662–4675
   PubMed Web of Science ®Google Scholar
• Harrington M. A., Konicek B., Song A., Xia X. L., Fredericks W. J., Rauscher F. J. I. Inhibition of colony-stimulating factor- promoter activity by the product of the Wilms' tumor locus. J Biological Chemistry 1993; 268: 21271–21275
   PubMed Web of Science ®Google Scholar
• Dey B. R., Sukhatme V. P., Roberts A. B., Sporn M. B., Rauscher F. J., 3rd, Kim S. J. Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. Mot Endocrinol 1994; 8: 595–602
   Web of Science ®Google Scholar
• Hewitt S. M., Hamada S., McDonnell T. J., Rauscher F. J., 3rd, Saunders G. F. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Rex 1995; 55: 5386–5389
   PubMed Web of Science ®Google Scholar
• Maheswaran S., Park S., Bernard A., Morris J. R., Rauscher F. J.D., Hill D. E., Haber D. A. Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci USA 1993; 90: 5100–5104
   PubMed Web of Science ®Google Scholar
• Maheswaran S., Englert C., Bennett P., Heinrich G., Haber D. A. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev 1995; 9: 2143–2156
   PubMed Web of Science ®Google Scholar
• Dehbi M., Ghahremani M., Lechner M., Dressier G., Pelletier J. The paired-box transcription factor. PAX2, positively modulates expression of the Wilms' tumor suppressor gene (WT1). Oncogene 1996; 13: 447–453
   PubMed Web of Science ®Google Scholar
• McConnell M. J., Cunliffe H. E., Chua L. J., Ward T. A., Eccles M. R. Differential regulation of the human Wilms tumour suppressor gene (WT1) promoter by two isoforms of PAX2. Oncogene 1997; 14: 2689–2700
   PubMed Web of Science ®Google Scholar
• Dehbi M., Hiscott J., Pelletier J. Activation of the WT1 Wilms' tumor suppressor gene by NF-kappaB. Oncogene 1998; 16: 2033–2039
   PubMed Web of Science ®Google Scholar
• Maheswaran S., Englert C., Lee S. B., Ezzel R. M., Settle-Man J., Haber D. A. E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells. Oncogene 1998; 16: 2041–2050
   PubMed Web of Science ®Google Scholar
• Rupprecht H. D., Drummond I. A., Madden S. L., Rauscher F. J., 3rd, Sukhatme V. P. The Wilms' tumor suppressor gene WT1 is negatively autoregulated. J Biol Chem 1994; 269: 6198–6206
   PubMed Web of Science ®Google Scholar
• Miwa H., Beran M., Saunders G. F. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992; 6: 405–409
   PubMed Web of Science ®Google Scholar
• Inoue K., Sugiyama H., Ogawa H., Nakagawa M., Yamagami T., Miwa H., Kita K., Hiraoka A., Masaoka T., Nasu K., et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071–3079
   PubMed Web of Science ®Google Scholar
• Brieger J., Weidmann E., Fenchel K., Mitrou P. S., Hoelzer D., Bergmann L. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia 1994; 8: 2138–2143
   PubMed Web of Science ®Google Scholar
• Menssen H. D., Renkl H. J., Rodeck U., Maurer J., Notter M., Schwartz S., Reinhardt R., Thiel E. Presence of Wilms' tumor gene (WT1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995; 9: 1060–1067
   PubMed Web of Science ®Google Scholar
• Brieger J., Weidmann E., Maurer U., Hoelzer D., Mitrou P. S., Bergmann L. The Wilms' tumor gene is frequently expressed in acute myeloblasts leukemias and may provide a marker for residual blast cells detectable by PCR. Ann Oncol 1995; 6: 811–816
   PubMed Web of Science ®Google Scholar
• Inoue K., Ogawa H., Yamagami T., Soma T., Tani Y., Tatekawa T., Oji Y., Tamaki H., Kyo T., Dohy H., Hiraoka A., Masaoka T., Kishimoto T., Sugiyama H. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996; 88: 2267–2278
   PubMed Web of Science ®Google Scholar
• Bergmann L., Miething C., Maurer U., Brieger J., Karakas T., Weidmann E., Hoelzer D. High levels of Wilms' tumor gene (wtl) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997; 90: 1217–1225
   PubMed Web of Science ®Google Scholar
• Menssen H. D., Renkl H. J., Rodeck U., Kari C., Schwartz S., Thiel E. Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia. lnt J Cancer 1997; 70: 518–523
   PubMed Web of Science ®Google Scholar
• Englert C., Vidal M., Maheswaran S., Ge Y., Ezzell R. M., Isselbacher K. J., Haber D. A. Truncated WT1 mutants alter the subnuclear localization of the wild- type protein. Proc Natl Acad Sci USA 1995; 92: 11960–11964
   PubMed Web of Science ®Google Scholar
• Larsson S. H., Charlieu J. P., Miyagawa K., Engelkamp D., Rassoulzadegan M., Ross A., Cuzin F., van Heyningen V., Hastie N. D. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell 1995; 81: 391–401
   PubMed Web of Science ®Google Scholar
• Menssen H. D., Renkl H.-J., Entezami M., Thiel E. Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early growth (letter). Blood 1997; 89: 3486–3487
   PubMed Web of Science ®Google Scholar
• Maurer U., Weidmann E., Karakas T., Hoelzer D., Bergmann L. Wilms tumor gene (WT1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors [letter]. Blood 1997; 90: 4230–4232
   PubMed Web of Science ®Google Scholar
• Baird P. N., Simmons P. J. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis [see comments]. Exp Hematol 1997; 25: 312–320
   PubMed Web of Science ®Google Scholar
• Inoue K., Ogawa H., Sonoda Y., Kimura T., Sakabe H., Oka Y., Miyake S., Tamaki H., Oji Y., Yamagami T., Tatekawa T., Soma T., Kishimoto T., Sugiyama H. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89: 1405–1412
   PubMed Web of Science ®Google Scholar
• Fraizer G. C., Patmasiriwat P., Zhang X., Saunders G. F. Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow [letter]. Blood 1995; 86: 4704–4706
   PubMed Web of Science ®Google Scholar
• Yamagami T., Sugiyama H., Inoue K., Ogawa H., Tatekawa T., Hirata M., Kudoh T., Akiyama T., Murakami A., Maekawa T. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligode-oxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 1996; 87: 2878–2884
   PubMed Web of Science ®Google Scholar
• Algar E. M., Khromykh T., Smith S. I., Blackburn D. M., Bryson G. J., Smith P. J. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene 1996; 12: 1005–1014
   PubMed Web of Science ®Google Scholar
• Campana D., Pui C.-H. Detection of minimal residual disease in acute leukemia: Methodologic advances and clinial significance. Blood 1995; 85: 1416–1434
   PubMed Web of Science ®Google Scholar
• Schmid D., Heinze G., Linnerth B., Tisljar K., Kusec R., Geissler K., Sillaber C., Laczika K., Mitterbauer M., Zoch-Bauer S., Mannhalter C., Haas O. A., Lechner K., Jager U., Gaiger A. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997; 11: 639–643
   PubMed Web of Science ®Google Scholar
• Gaiger A., Schmid D., Heinze G., Linnerth B., Greinix H., Kalhs P., Tisljar K., Priglinger S., Laczika K., Mitterbauer M., Novak M., Mitterbauer G., Mannhalter C., Haas O. A., Lechner K., Jager U. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 1998; 12: 1886–1894
   PubMed Web of Science ®Google Scholar
• Bain B. J. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. Br J Haematol 1996; 95: 2–9
   PubMed Web of Science ®Google Scholar
• Parreira L., Tavares de Castro J., Hibbin J. A., Marsh J. C., Marcus R. E., Babapulle V. B., Spry C. J., Goldman J. M., Catovsky D. Chromosome and cell culture studies in eosinophilic leukaemia. Br J Haematol 1986; 62: 659–669
   PubMed Web of Science ®Google Scholar
• Weide R., Rieder H., Mehraein Y., Wolf M., Kaiser U., Seifart U., Gorg C., Havemann K. Chronic eosinophilic leukaemia (CEL): a distinct myeloproliferative disease. Br J Haematol 1997; 96: 117–123
   PubMed Web of Science ®Google Scholar
• Chusid M. J., Dale D. C., West B. C., Wolff S. M. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54: 1–27
   PubMed Web of Science ®Google Scholar
• Weller P. F., Bubley G. J. The idiopathic hypereosinophilic syndrome. Blood 1994; 83: 2759–2779
   PubMed Web of Science ®Google Scholar
• Raghavachar A., Fleischer S., Frickhofen N., Heimpel H., Fleischer B. T lymphocyte control of human eosinophilic granulopoiesis. Clonal analysis in an idiopathic hypereosinophilic syndrome. J Immunol 1987; 139: 3753–3758
   PubMed Web of Science ®Google Scholar
• Owen W. R., Rothenberg M. E., Petersen J., Weller P. F., Silberstein D., Sheffer A. L., Stevens R. L., Soberman R. J., Austen K. F. Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. J Exp Med 1989; 170: 343–348
   PubMed Web of Science ®Google Scholar
• Menssen H. D., Renkl H. J., Rieder H., Bartelt S., Schmidt A., Notter M., Thiel E. Distinction of eosinophilic leukaemia from idiopathic hypereosinophilic syndrome by analysis of Wilms' tumour gene expression. Br J Haematol 1998; 101: 325–334
   PubMed Web of Science ®Google Scholar